Mersana Therapeutics (MRSN) said Friday that the US Food and Drug Administration recently granted an additional Fast Track designation to XMT-1660 for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease, including triple-negative breast cancer, who have received a prior topoisomerase-1 inhibitor antibody-drug conjugate, the company said.
The FDA previously granted the drug Fast Track designation for the treatment of adult patients with advanced or metastatic recurrent triple-negative breast cancer.
The company also said that the World Health Organization has approved emiltatug ledadotin as XMT-1660's international nonproprietary name.
Shares of the company were up more than 15% in Friday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.